Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and Ca
(+)-catharanthine
18-Methoxycoronaridine
Coronaridine congeners
Neuropathic pain
Nicotinic acetylcholine receptors
Voltage-gated (Ca(V)2.2) calcium channels
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
31
01
2020
revised:
04
06
2020
accepted:
08
06
2020
pubmed:
17
6
2020
medline:
24
9
2021
entrez:
17
6
2020
Statut:
ppublish
Résumé
The primary aim of this study was to determine the anti-neuropathic activity of (±)-18-methoxycoronaridine [(±)-18-MC] and (+)-catharanthine in mice by using the oxaliplatin-induced neuropathic pain paradigm and cold plate test. The results showed that both coronaridine congeners induce anti-neuropathic pain activity at a dose of 72 mg/kg (per os), whereas a lower dose (36 mg/kg) of (+)-catharanthine decreased the progress of oxaliplatin-induced neuropathic pain. To determine the underlying molecular mechanism, electrophysiological recordings were performed on α9α10, α3β4, and α4β2 nAChRs as well as voltage-gated calcium (Ca
Identifiants
pubmed: 32540451
pii: S0028-3908(20)30262-8
doi: 10.1016/j.neuropharm.2020.108194
pii:
doi:
Substances chimiques
Analgesics
0
Cav2 protein, mouse
0
Caveolin 2
0
Receptors, Nicotinic
0
Vinca Alkaloids
0
Ibogaine
3S814I130U
18-methoxycoronaridine
KX8NQX91Z8
catharanthine
WT0YJV846J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108194Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.